Coherus BioSciences (CHRS -4.9%) is under pressure on modestly higher volume after it announced that USPTO denied all four of its petitions for Inter Partes review of AbbVie's (ABBV +6.2%) U.S. Patent No. 9,085,619 protecting HUMIRA (adalimumab).
CEO Denny Lanfear says, “While we are disappointed by this outcome, we continue to develop and refine our legal strategies for addressing any patents, including formulation patents, that AbbVie may assert in District Court proceedings."
Now read: A Double Beat For AbbVie »
Subscribe for full text news in your inbox